152 related articles for article (PubMed ID: 37914528)
21. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
[TBL] [Abstract][Full Text] [Related]
23. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of mesothelin expression in colorectal cancer disclosed by area-specific four-point tissue microarrays.
Shiraishi T; Shinto E; Nearchou IP; Tsuda H; Kajiwara Y; Einama T; Caie PD; Kishi Y; Ueno H
Virchows Arch; 2020 Sep; 477(3):409-420. PubMed ID: 32107600
[TBL] [Abstract][Full Text] [Related]
25. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Gynecol Oncol; 2016 Jun; 141(3):447-453. PubMed ID: 27072806
[TBL] [Abstract][Full Text] [Related]
26. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
27. AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.
Saglam O; Husain S; Toruner G
Int J Gynecol Pathol; 2013 Sep; 32(5):493-500. PubMed ID: 23896716
[TBL] [Abstract][Full Text] [Related]
28. Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer.
Inoue S; Tsunoda T; Riku M; Ito H; Inoko A; Murakami H; Ebi M; Ogasawara N; Pastan I; Kasugai K; Kasai K; Ikeda H; Inaguma S
Oncol Lett; 2020 Mar; 19(3):1741-1750. PubMed ID: 32194667
[TBL] [Abstract][Full Text] [Related]
29. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
30. Exploring biomarkers and prognostic factors in uterine carcinosarcoma: An insight into L1CAM, CDX2, p53, and MSI status.
da Silva JL; de Albuquerque LZ; Rodrigues FR; Bastos NC; Small IA; Barroso EBC; Cordero FL; Fernandes DS; Paulino E; de Melo AC
PLoS One; 2023; 18(5):e0285447. PubMed ID: 37200263
[TBL] [Abstract][Full Text] [Related]
31. Mesothelin Expression is Correlated with Chemoresistance in Stage IV Colorectal Cancer.
Nagata K; Shinto E; Shiraishi T; Yamadera M; Kajiwara Y; Mochizuki S; Okamoto K; Einama T; Kishi Y; Ueno H
Ann Surg Oncol; 2021 Dec; 28(13):8579-8586. PubMed ID: 34318385
[TBL] [Abstract][Full Text] [Related]
32. Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors.
Weidemann S; Gagelmann P; Gorbokon N; Lennartz M; Menz A; Luebke AM; Kluth M; Hube-Magg C; Blessin NC; Fraune C; Möller K; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Izbicki JR; Jansen K; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Burandt E; Krech RH; Dum D; Krech T; Marx AH; Simon R
Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33917081
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases.
Jones TE; Pradhan D; Dabbs DJ; Bhargava R; Onisko A; Jones MW
Int J Gynecol Pathol; 2021 Jan; 40(1):84-93. PubMed ID: 31855950
[TBL] [Abstract][Full Text] [Related]
34. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
35. Significance of mesothelin expression in preoperative endoscopic biopsy specimens for colorectal cancer prognosis.
Shiraishi T; Shinto E; Yamadera M; Nagata K; Tsuda H; Mochizuki S; Kajiwara Y; Okamoto K; Einama T; Kishi Y; Ueno H
Oncotarget; 2020 Oct; 11(43):3807-3817. PubMed ID: 33196692
[TBL] [Abstract][Full Text] [Related]
36. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
[TBL] [Abstract][Full Text] [Related]
38. Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment.
Hilliard TS; Kowalski B; Iwamoto K; Agadi EA; Liu Y; Yang J; Asem M; Klymenko Y; Johnson J; Shi Z; Marfowaa G; Yemc MG; Petrasko P; Stack MS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830322
[TBL] [Abstract][Full Text] [Related]
39. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
Menderes G; Bonazzoli E; Bellone S; Black J; Predolini F; Pettinella F; Masserdotti A; Zammataro L; Altwerger G; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Clin Cancer Res; 2017 Oct; 23(19):5836-5845. PubMed ID: 28679774
[No Abstract] [Full Text] [Related]
40. Gynecological carcinosarcomas: Overview and future perspectives.
Collet L; González López AM; Romeo C; Méeus P; Chopin N; Rossi L; Rowinski E; Serre AA; Rannou C; Buisson A; Treilleux I; Ray-Coquard I
Bull Cancer; 2023 Nov; 110(11):1215-1226. PubMed ID: 37679206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
